The U.S. Department of Defense (DOD) Defense Health Agency awarded a $911,151 Project Grant on February 15, 2025 to The Regents of the University of Colorado under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 2-year research effort to develop PEG10 inhibitors as potential therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). As a leading public research university, the University of Colorado will leverage its expertise in bioscience, molecular biology, and drug development to advance this fundamental research project aimed at expanding scientific knowledge and addressing critical health challenges for military personnel and the general public.
Generated 3/4/25, 7:07 AM